News
-
Swisse self-regulation
Wednesday | Mar 22 2017COMPLEMENTARY products maker Swisse has made a pre-budget submission urging the government to implement a self-regulation model for advertising of complementary medicines.
-
AFT seals NovoTears deal
Wednesday | Mar 22 2017AFT Pharmaceuticals yesterday confirmed a new licensing agreement with German specialty pharmaceutical company to distribute NovaTears in Australia and New Zealand.
-
Compounding feedback
Wednesday | Mar 22 2017THE Pharmaceutical Society of Australia is seeking submissions on its revised Compounding Standard, yesterday releasing a consultation paper which is open to feedback until 18 Apr 2017.
-
Guild Update 21 Mar 17
Tuesday | Mar 21 2017APP2017 was once again a resounding success in a great many ways; one of which was the way in which it highlighted the willingness and enthusiasm of community pharmacists to adopt new models of doing business.
-
AstraZeneca zones in
Tuesday | Mar 21 2017BIOPHARMACEUTICAL giant AstraZeneca has invested in new futuristic Sydney offices with four "zones" for varying styles of productive work.
-
New pathway consult
Tuesday | Mar 21 2017THE TGA is inviting submissions on a new Provisional Approval pathway for prescription medicines, which will allow sponsors to seek a "time-limited provisional registration" of drugs that do not meet full clinical data requirements.
-
Pharmacist suspended
Tuesday | Mar 21 2017THE registration of a Tasmanian pharmacist was suspended for six weeks earlier this year, after he admitted to professional misconduct in relation to inappropriate supply of scheduled medications and inadequate record keeping.
-
NatRUM alerts to med risks
Tuesday | Mar 21 2017JUST 18% of Australians are aware of the National Return and Disposal of Unwanted Medicines (NatRUM) scheme, with most people simply putting unused drugs into their household rubbish.
-
EpiPen auto-injector recall
Tuesday | Mar 21 2017ALPHAPHARM, in consultation with the Therapeutic Goods Administration (TGA), has announced it is recalling four batches of EpiPen 300 microgram adrenaline injection syringe auto-injectors, due to the potential failure to activate or the need to apply increased force to activate the device.